Adalimumab for long-term treatment of ps
β
Dafna D. Gladman; Philip J. Mease; Christopher T. Ritchlin; Ernest H. S. Choy; J
π
Article
π
2007
π
John Wiley and Sons
π
English
β 281 KB
π 2 views
## Abstract ## Objective To evaluate the efficacy and safety of treatment with adalimumab, a fully human antiβtumor necrosis factor (antiβTNF) monoclonal antibody, over 48 weeks in patients with moderate to severe psoriatic arthritis (PsA). ## Methods Patients who completed the Adalimumab Effect